The Silverstein Foundation In the News
The Silverstein Foundation has been featured in national and international publications and broadcast media.
News articles & blog posts
Vanqua Bio closes $85 million Series B financing
Silverstein Foundation Announces Grant Funding to AcureX Therapeutics.
Prevail Announces First Patient Dosed
Prevail Therapeutics Acquired by Lilly
Aspen Neuroscience Announces $70 Million Series A Financing
Silverstein Foundation Annual Update
First and foremost, we hope this finds you and your family well and safe. These are unprecedented times, and we are keenly aware of the challenges that so many around the globe are facing. While we do what we can individually to stop the spread of coronavirus, we...
The Silverstein Foundation and Q-State Biosciences Launch Chamishi Therapeutics
NEW YORK and CAMBRIDGE, Mass., Sept 26, 2019 (GLOBE NEWSWIRE) – The Silverstein Foundation for Parkinson’s with GBA and Q-State Biosciences today announced the formation and launch of Chamishi Therapeutics, a drug discovery and development company focused on...
Prevail Therapeutics Announces Pricing of Initial Public Offering
NEW YORK--(BUSINESS WIRE)--Jun. 19, 2019-- Prevail Therapeutics Inc. (Nasdaq: PRVL) (Prevail), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today announced the...
Prevail Therapeutics Announces IND Active for Phase 1/2 Trial of its Gene Therapy PR001
NEW YORK--(BUSINESS WIRE)--Jun 4, 2019-- Prevail Therapeutics Inc. (Prevail), a gene therapy company developing AAV-based gene therapies for patients with neurodegenerative diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted the...
The Michael J. Fox Foundation and The Silverstein Foundation for Parkinson’s with GBA Grant Nearly $3 Million to Studies into Disease’s Most Common Known Genetic Contributor
NEW YORK (February 20, 2019) - The Michael J. Fox Foundation for Parkinson's Research (MJFF) and The Silverstein Foundation for Parkinson's with GBA announce nearly $3 million in grants to studies investigating glucocerebrosidase beta acid (GBA). Mutations in the GBA...
Video
CNBC: Investing in a cure
August, 2017—Wall Street investor Jonathan Silverstein has spent a career finding and funding biotech firms working on cures for rare diseases. But after learning in February he has Parkinson’s Disease, the diagnosis set him and his wife on a path to create a different kind of startup, a foundation to work towards a cure.
CNBC: Venture capitalist wages war against Parkinson’s, searches for miracle after his own diagnosis
August, 2017—It’s been less than a year since Jonathan Silverstein, a venture capitalist at health-care fund OrbiMed, received the diagnosis that changed everything.